GRI's common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024      LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-13 reverse stock split (the "Reverse Split") of the Company' ...